Forum threads do not raise the 20 mg vardenafil stop

Forum praise does not lift Levitra past 20 mg

Forum praise does not lift Levitra past 20 mg. One PRN tablet in twenty-four hours. Oral bioavailability sits near 15%. A high-fat plate delays and blunts the peak. The card is a ceiling note, not a checkout.

Staxyn and swallowed vardenafil are not a 20 mg swap

Staxyn and swallowed vardenafil share a moiety and split on food, Cmax, and how the bottle is labeled. Class IA or III antiarrhythmics stay on the stop list for both. Do not treat them as a 20 mg swap.

Grocery coupon rows for 10 mg and 20 mg vardenafil

CVS, Target, Publix, and Harris Teeter already publish coupon numbers. August 2026 snapshots. 10 mg and 20 mg rows are not interchangeable. ZIP moves the dollar.

The Third PDE5 Pill - Still on the Shelf for a Reason

Vardenafil occupies a narrower market share but fills a legitimate niche in PDE5 rotation strategies - especially among men with diabetes who were well represented in its registration program.

Vardenafil arrived months before tadalafil in 2003 as Bayer/GSK's entry into the post-sildenafil market. Uptake never matched Viagra or Cialis culturally, but the molecule remains available as generic vardenafil and orodispersible Staxyn in some markets.

Prescribers reach for it when sildenafil causes unacceptable visual symptoms, when tadalafil myalgia dominates, or when a patient had a good response in past trials of vardenafil specifically - continuity matters more than theoretical potency rankings.

Formulary committees often drop vardenafil first when trimming duplicate PDE5 agents. That is a cost decision, not a pharmacologic verdict: head-to-head efficacy at labeled doses overlaps the class.

Cardiology-heavy practices remember vardenafil for QT prolongation language in labeling - a concern that matters mainly when combining with class IA or III antiarrhythmics or other QT-prolonging drugs, not for every man with a normal baseline ECG.

Understanding vardenafil teaches that bench IC50 values do not prescribe themselves. Low bioavailability and food effects mean milligram potency in a test tube translates to modest plasma levels after a cheeseburger.

Market withdrawal of vardenafil occurred in some countries while U.S. generic supply continues - check local availability before rotating patients off sildenafil.

Card note: men who report blue vision on sildenafil sometimes tolerate vardenafil better - anecdotal but consistent with PDE6 selectivity data; still trial one dose before dispensing a three-month supply.

Staxyn ODT availability varies; film-coated generic vardenafil is the usual dispense in 2020s formularies.

Diabetic microvascular disease lowers baseline NO bioavailability; vardenafil registration enriched diabetic cohorts precisely because marketing and clinical need aligned - subgroup data are among the better in-class numbers for glycemic patients.

Card note: prostate cancer survivors on ADT develop ED from androgen deprivation plus neurovascular injury; vardenafil does not treat libido loss from castrate testosterone but may assist rigidity when libido returns on BRA therapy breaks.

Occupational pilots and commercial drivers ask about PDE5 use - FAA and DOT policies require reporting and ground until stable on therapy; vardenafil half-life supports return-to-duty timing similar to sildenafil after single PRN dose.

Card note: combination with intracavernosal injection in refractory diabetic ED is urology territory - oral vardenafil 20 mg same day as injection requires specialist protocol to avoid priapism synergy.

Formulary committees comparing cost per successful intercourse often model sildenafil first, tadalafil daily second, vardenafil third - absence from formulary is economic not evidence-based deprioritization.

Card note: men referred from endocrinology for ED on testosterone replacement should continue vardenafil trials if rigidity remains insufficient after normalized testosterone - androgen restoration alone does not always restore erectile hemodynamics.

PDE5 Blockade with High Binding Affinity

Vardenafil inhibits PDE5-catalyzed cGMP hydrolysis in corpus cavernosum smooth muscle. Nitric oxide released during sexual stimulation still provides the upstream signal; without arousal, clinically meaningful erection does not occur.

Card note: in vitro, vardenafil shows the lowest IC50 against PDE5 among the original three oral agents - roughly 0.7 nM in some assay summaries versus low nanomolar values for sildenafil and tadalafil. Selectivity over PDE6 is better than sildenafil at equivalent PDE5 inhibition in certain models, which may translate to fewer color-vision complaints for some patients.

PDE1 inhibition at supratherapeutic concentrations can contribute to vasodilation; at 20 mg labeled doses this is not a primary clinical issue in normotensive men.

Card note: protein kinase G activation downstream of cGMP remains the effector pathway for smooth muscle relaxation and increased cavernosal blood flow. Systemic arterial vasodilation produces mild blood pressure reduction - monitor when adding to antihypertensive stacks.

As with all PDE5 inhibitors, combining vardenafil with nitrates or riociguat is forbidden because cGMP accumulates via complementary mechanisms and can crash blood pressure.

Orodispersible formulations dissolve on the tongue and enter systemic circulation partly through oral mucosa - slightly different PK than swallowed film-coated tablets, though total bioavailability remains meal-sensitive for the swallowed fraction.

M1 metabolite kinetics extend effective PDE5 inhibition beyond parent half-life when CYP3A4 is blocked - same pattern as sildenafil's N-desmethyl metabolite but with lower relative potency (~26%).

Vardenafil does not meaningfully inhibit or induce CYP450 enzymes at ED doses - interaction profile is substrate-only via 3A4, not perpetrator.

Thorough QT study at 10 mg showed no clinically relevant QTc prolongation; concern emerges mainly with concurrent QT drugs or overdose.

Vardenafil HCl salt form affects aqueous solubility and tablet hardness; generic manufacturers must meet USP dissolution specs - occasional patient reports of 'different feel' rarely reflect bioinequivalence if AB-rated.

Combined alpha-blocker and vardenafil study with tamsulosin 0.4 mg daily showed symptomatic orthostasis in a minority at first co-administration - observe and counsel, do not dismiss as psychogenic.

Low Bioavailability and the Meal Penalty

Oral bioavailability of vardenafil is approximately 15% - lower than sildenafil's ~41% - with extensive first-pass metabolism via CYP3A4 and smaller contributions from CYP2C9 and CYP2C19.

Median Tmax is about 60 minutes under fasting conditions, similar to sildenafil. High-fat meals reduce Cmax by roughly 18-50% depending on study definition and delay Tmax by about an hour - label recommends avoiding high-fat meals near dosing when possible.

Terminal half-life is about 4-5 hours in healthy volunteers - between sildenafil and tadalafil. A major metabolite, M1, has roughly 26% of parent PDE5 inhibitory activity and contributes to net effect, especially when CYP3A4 is inhibited.

Protein binding is about 95%. Volume of distribution near 208 L in labeling. Hepatic impairment increases exposure: Child-Pugh class B starts at 5 mg; class C contraindicates use.

Renal impairment does not dramatically alter vardenafil PK except at dialysis-stage disease where 5 mg maximum is recommended. Hemodialysis removes negligible drug.

Card note: staxyn orodispersible 10 mg tablets are not bioequivalent milligram-for-milligram to Levitra 10 mg film-coated - switching forms requires prescriber recalculation, not pharmacy auto-substitution.

Cmax at 20 mg fasted reaches roughly 18 ng/mL in label PK tables - lower absolute exposure than sildenafil 100 mg despite higher potency because of bioavailability ceiling.

Grapefruit juice interaction is listed - practical significance is modest for occasional consumption but avoid liter-scale intake near dosing.

Indinavir and other protease inhibitors require 5 mg cap identical to ketoconazole interaction studies.

Renal clearance contributes only 2-6% of elimination; dose adjustment in dialysis is conservative because parent drug is highly bound - 5 mg PRN is typical ceiling.

Vardenafil AUC increases about 20-30% in elderly versus young volunteers at 20 mg - label recommends considering 5 mg start in men over 65, not because of frailty stereotypes but because PK data support it.

Pivotal Trials with Diabetic Enrichment

FDA approval in August 2003 rested on the same IIEF and diary framework as sildenafil and tadalafil, with notable enrollment of diabetic men.

Registration trials randomized men to vardenafil 5, 10, or 20 mg or placebo taken about one hour before intercourse. Primary endpoints mirrored the class: IIEF erectile function domain change and diary-based successful penetration and intercourse.

Card note: all doses separated from placebo on IIEF and intercourse success. Twenty milligrams produced maximum benefit; five milligrams sufficed for some mild ED cases but underperformed in moderate vasculogenic disease.

Diabetic ED was studied in dedicated trials and as prespecified subgroups - response rates remained superior to placebo though lower than in nondiabetic cohorts, consistent with neuropathic and microvascular compromise.

Onset typically 30-60 minutes fasted; duration of action aligns with 4-5 hour half-life plus active M1 metabolite - practical window similar to sildenafil rather than tadalafil.

Fixed-dose titration studies supported the 5 → 10 → 20 mg ladder. Flexible dosing improved patient satisfaction in some open-label extensions without increasing serious AE rates.

Card note: indirect comparison meta-analyses do not show vardenafil superiority over sildenafil or tadalafil for IIEF when doses are equipotent and food effects managed - marketing potency claims do not translate to doubled rigidity in clinic.

Post-marketing use in post-prostatectomy ED follows class patterns: some benefit, many need multimodal rehabilitation.

Card note: diabetic subgroup analyses showed odds ratios favoring vardenafil over placebo comparable to sildenafil diabetic trials - useful when formulary keeps vardenafil as tier-2 after generic sildenafil failure.

Flexible dosing trials allowed 10 or 20 mg choice per encounter; satisfaction scores improved versus fixed 10 mg arms in some analyses.

Laboratory penile plethysmography studies show increased rigidity versus placebo at 60 minutes post-dose - correlates with clinical onset counseling.

Card note: diabetic ED trial prespecified vardenafil 10 and 20 mg arms with HbA1c-stratified analyses - response remained superior to placebo even when HbA1c exceeded 8% in subset tables, though absolute success fell.

Non-inferiority to sildenafil was not the registration path; vardenafil stood on independent IIEF data - cross-trial comparison is indirect and should not drive 'stronger drug' patient messaging.

Fixed-dose vardenafil 5, 10, and 20 mg arms in primary registration showed dose-dependent increases in IIEF-EF and SEP2/SEP3 success rates; 5 mg was minimally effective in moderate-to-severe ED, anchoring 10 mg as practical start.

Diabetes-specific trial (DMED study design class) enrolled men with HbA1c-controlled type 2 diabetes; vardenafil 10 and 20 mg beat placebo on IIEF with absolute intercourse success rates roughly 15-20 percentage points above placebo.

Duration of action in labeling states up to 5 hours for vardenafil - shorter than tadalafil marketing but comparable to sildenafil; patient expectations should be calibrated to half-life class, not in vitro potency rank.

Placebo run-in periods in vardenafil trials washed out psychogenic responders partially - per-protocol analyses excluding non-adherent patients show higher success than ITT, relevant when counseling real-world adherence.

SEP3 (successful intercourse) responder rates at vardenafil 20 mg approximated 65-75% in general ED populations versus 30-40% placebo - diabetic cohorts ran roughly 10-15 percentage points lower on same endpoint.

IIEF intercourse satisfaction domain improved secondary to erectile function gains - partners were not primary endpoints but male-reported satisfaction scores rose in parallel with SEP success.

Flexible-dose extension studies allowed men to choose 5, 10, or 20 mg per encounter after initial fixed-dose period - majority settled on 10 or 20 mg, supporting individualized titration as standard care.

Comparison with tadalafil in open-label crossover trials showed split preference without superiority on rigidity metrics - reinforces agent selection by lifestyle not laboratory potency.

Vardenafil registration did not include daily dosing arm - all labeled use is PRN; off-label daily vardenafil lacks PK justification unlike tadalafil half-life rationale.

5-20 mg Ladder and Formulation Rules

Initial dose: 10 mg orally approximately 60 minutes before sexual activity. Adjust to 20 mg if tolerated and inadequate, or to 5 mg if side effects occur. Maximum one dose per 24 hours.

Card note: men 65 years and older may achieve higher plasma levels at the same dose - consider 5 mg start when frail or on multiple vasodilators.

Hepatic Child-Pugh class B: maximum 5 mg. Child-Pugh class C: do not use - contraindicated per label.

Potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, indinavir, clarithromycin): maximum 5 mg vardenafil in 24 hours. Moderate inhibitors (erythromycin): 5 mg starting dose prudent.

Card note: alpha-blockers: if stable on tamsulosin, vardenafil 10 mg has been studied with orthostatic monitoring; other alpha-blockers require stable dose and 5 mg vardenafil start.

Do not combine with other PDE5 inhibitors. High-fat meal timing counseling matches sildenafil: plan dose before appetizer course, not after dessert.

If 10 mg causes headache but partial response, 5 mg retry before abandoning agent - potency per mg is high but bioavailability limits peak exposure.

Orodispersible Staxyn 10 mg is not substitutable for 10 mg film-coated; prescriber must specify formulation on e-script.

Surgery and anesthesia: no mandatory washout in label but inform anesthesiologist of recent PDE5 use for hemodynamic planning.

Film-coated 20 mg maximum once daily - taking two 10 mg tablets to reach 20 mg is label-appropriate; taking two 20 mg tablets is overdose territory with hypotension and vision symptoms.

Vardenafil labeling allows dosing 60 minutes before activity with flexibility similar to sildenafil; fasted onset remains the predictable anchor.

Card note: ketoconazole 400 mg daily increased vardenafil AUC approximately 10-fold and Cmax about 4-fold - mandatory 5 mg cap is not optional counseling nuance.

Erythromycin 500 mg TID moderate inhibition: start vardenafil 5 mg and titrate - exposure rises less than with azole antifungals but still clinically relevant.

QT Drugs, CYP3A4, Nitrates, Alpha Blockers

Vardenafil's interaction profile is class-standard on nitrates and CYP3A4, with extra QT language that earns a second look at the medication list in men on amiodarone or sotalol.

Nitrates and nitrites: absolute contraindication - identical hemodynamic catastrophe risk as other PDE5 agents.

Riociguat: contraindicated.

QT prolongation: vardenafil at 10 mg does not prolong QTc by more than 10 ms in thorough QT studies at therapeutic dose, but labeling warns against combination with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics and other QT-prolonging drugs (certain macrolides, antipsychotics). Risk rises at supratherapeutic doses.

Potent CYP3A4 inhibitors dramatically increase vardenafil exposure - ketoconazole 400 mg daily raised vardenafil AUC about 10-fold in interaction studies; 5 mg cap is mandatory.

Alpha-1 blockers add orthostatic hypotension; stable tamsulosin regimens were studied with 10 mg vardenafil - still check seated and standing BP at first combination dose.

Moderate CYP3A4 inducers may reduce efficacy; heavy grapefruit juice may increase exposure - practical counseling point though rarely decisive alone.

Class IA antiarrhythmics (quinidine) and class III (amiodarone, sotalol) are called out in labeling - run QT risk score if patient takes vardenafil plus antipsychotic or macrolide.

Nitrates within 24 hours remain contraindicated; some European labels differ on washout hours from U.S. practice - follow local PI when treating travelers.

Verapamil and diltiazem moderate 3A4 inhibition: consider 5 mg vardenafil start when adding to existing calcium channel blocker regimen.

Card note: amiodarone loading during AF initiation overlaps with vardenafil poorly - defer PDE5 start until amiodarone steady state and QT reassessment if possible.

Grapefruit single glass with breakfast is unlikely to matter; daily large-volume intake during ketoconazole-sparing regimens still deserves mention.

Headache, Flushing, Vision - and QT Context

Headache, flushing, rhinitis, dyspepsia, and dizziness lead incidence tables - dose-related and time-limited for most men. Headache rates parallel other PDE5 agents at comparable effective doses.

Visual disturbance occurs less frequently than with sildenafil in some comparative reports, possibly reflecting PDE6 selectivity - still monitor for sudden vision loss (NAION) as class warning.

Priapism remains rare; sickle cell and hematologic malignancy patients need explicit emergency instructions.

Sudden hearing loss - class warning; discontinue and evaluate.

Back pain and myalgia occur but less prominently than with tadalafil in pooled comparisons - useful when switching agents for musculoskeletal AE.

At 20 mg, vardenafil can produce larger blood pressure drops than placebo in BP studies - relevant for men on multiple antihypertensives or borderline hypotensive at baseline.

Rhinitis incidence parallels other PDE5 agents; intranasal decongestants are not contraindicated but sympathomimetic stacks may raise BP variably.

Syncope with first dose usually implicates alpha-blocker co-administration - observe 2-hour seated BP after first combination in clinic when feasible.

Card note: headache rates at vardenafil 20 mg approximate 15% in pooled trials - slightly lower visual disturbance reports than sildenafil 100 mg in some head-to-head patient surveys though trials were not powered for AE superiority.

Priapism management is identical across PDE5 class: urology emergency, aspiration first line, avoid second oral PDE5 dose while priapism persists.

Diabetes, Elderly, Hepatic, and Cardiac Subgroups

Type 2 diabetes: registration subgroups demonstrated maintained superiority versus placebo; start standard 10 mg but expect more frequent need for 20 mg or agent switch compared with nondiabetic men.

Elderly men clear drug more slowly; 5 mg initial dose reduces headache and orthostasis without sacrificing efficacy in many.

Child-Pugh A: no adjustment. Class B: 5 mg max. Class C: contraindicated.

Card note: severe renal impairment (CrCl <30): limited data - 5 mg maximum prudent; dialysis does not require supplemental dosing.

Card note: stable coronary artery disease without nitrates: sexual activity and vardenafil use were studied in subsets of cleared patients - individualized cardiology input for recent MI or unstable symptoms.

Retinitis pigmentosa: relative contraindication shared across PDE5 class.

Women partners occasionally contact poison control after ingesting vardenafil accidentally - low systemic exposure from single tablet rarely causes serious harm but counsel secure storage.

Parkinson disease with autonomic dysfunction: start 5 mg and monitor orthostasis - ED is common but falls risk is higher.

Active peptic ulcer disease is not contraindicated but dyspepsia may worsen - co-prescribe PPI if needed after dose optimization.

Type 1 diabetes with autonomic neuropathy shows lower vardenafil response in observational cohorts than type 2 at similar HbA1c - set expectations and optimize glucose before dose escalation beyond 20 mg.

Child-Pugh class B caps vardenafil at 5 mg; class C contraindication is absolute in label - men with decompensated cirrhosis need non-oral ED strategies.

Multiple myeloma and leukemia priapism risk counseling applies equally to vardenafil - hematology-oncology patients may need lower starting 5 mg and explicit emergency instructions.

Spinal cord injury T6 and above with autonomic dysreflexia history: coordinate with rehab physician before adding any vasodilator including vardenafil - blood pressure spikes during intercourse independent of drug.

Obstructive sleep apnea and ED cluster; CPAP adherence sometimes improves erectile function enough to reduce PDE5 dose - treat sleep disorder concurrently.

Questions From the Cardiology Clinic and the Bedroom

'I take amiodarone - is Levitra safe?' - Probably avoid; QT and hypotensive stacking. Pick another strategy or resolve arrhythmia drug first with electrophysiology.

'Same as Viagra timing?' - Similar fasted onset near an hour; same fatty-meal delay. Different pill, parallel rules.

'Can the pharmacist swap Staxyn for generic tablets?' - No without new prescription; bioavailability differs.

'I'm diabetic and failed sildenafil 100 mg' - Vardenafil 20 mg worth a structured trial before declaring class failure; optimize glucose and BP first.

Wallet card for nitrates: 24-hour washout minimum; tell EMS regardless of which PDE5 agent they took.

QT drugs review: run the prescription through your institution's QT checker when adding vardenafil to psychotropic or antiarrhythmic regimens.

'Is this the strongest one?' - Strongest in the lab, not automatically in your bedroom; 20 mg vardenafil still loses to poor arousal or heavy meals.

Show pill photo to patient - generic vardenafil shapes differ and cause confusion with other blue tablets (e.g., sildenafil generics).

Men on amiodarone for atrial fibrillation should generally avoid vardenafil - QT and hemodynamic overlap; consider referral for arrhythmia drug optimization before any PDE5 trial.

Vardenafil film-coated tablets should be swallowed; Staxyn ODT placed on tongue without water - patients who confuse formulations get unpredictable onset when they swallow ODT with large meal.

Diabetic peripheral neuropathy severity correlates with treatment failure more than HbA1c alone in observational registries - optimize glycemic control and address pain medications that worsen ED before declaring vardenafil ineffective.

Prescriber Takeaways for Vardenafil

Card note: vardenafil is a potent PDE5 inhibitor on paper with ~15% oral bioavailability and meal-sensitive absorption - clinical window resembles sildenafil, not tadalafil.

Standard dose: 10 mg PRN, titrate 5-20 mg, max once daily. Hepatic impairment and CYP3A4 inhibitors cap at 5 mg.

Diabetic ED data are robust within class; use as rotation option when peers fail or cause intolerable AEs.

Nitrates, nitrites, riociguat contraindicated; alpha-blockers need stable baseline and cautious first co-dose.

QT prolongation labeling matters for men on class IA/III antiarrhythmics or QT-prolonging psychotropics - not for every patient, but scan the list.

Orodispersible and film-coated forms are not interchangeable; food still blunts exposure for swallowed components.

Keep vardenafil in rotation algorithms when visual side effects limit sildenafil and myalgia limits tadalafil - niche but real.

Card note: document QT-related medication list at initiation when prescribing to cardiology-heavy panels.

Vardenafil 10 mg produced mean maximal decrease in blood pressure of roughly 7 mmHg systolic and 8 mmHg diastolic greater than placebo in standing position in label hemodynamic studies - small means hide outliers who syncopize.

When formulary removes vardenafil, document agent trials in chart so prior authorization for re-add has clinical justification.

Levitra patent expiry produced multiple AB-rated generics; patient counseling on tablet appearance reduces anxiety when color shifts from brand orange to generic white.

Card note: vardenafil remains viable when formulary tiering places it below tadalafil brand but above sildenafil - know your institution's tier list before automatic substitution.

Bench IC50 0.7 nM versus sildenafil low nanomolar range does not mean use 25 mg vardenafil equals 100 mg sildenafil - bioavailability and protein binding dominate clinic outcomes, not test-tube potency alone.

Post-marketing surveillance for vardenafil mirrors class on NAION and hearing loss; no agent-specific REMS but FAERS review continues periodically.

Thorough QT study (TQT) at therapeutic 10 mg and supratherapeutic 30 mg and 80 mg doses informed FDA labeling - therapeutic dose did not exceed 10 ms QTc threshold; supratherapeutic did, anchoring maximum 20 mg ED cap.

Vardenafil HCl trihydrate salt in original Levitra formulation affects tablet weight versus generic anhydrous forms - pharmacy billing uses same NDC family but pill weight differs; irrelevant clinically if dissolution specs met.

M1 metabolite half-life parallels parent; CYP3A4 blockade prolongs both moieties - same interaction counseling as sildenafil metabolite but with lower relative M1 potency.

European Union public assessment report mirrors U.S. diabetic subgroup efficacy conclusions - useful when patients relocate mid-treatment.

Intracavernosal pressure measurements in animal models show vardenafil augments electrically stimulated erections more than spontaneous - reinforces arousal requirement in human counseling.

When all three oral PDE5 agents fail after optimized trials, next steps are vacuum device, intracavernosal alprostadil, or urology referral - vardenafil completion of class trial is checklist item before invasive therapy.

Standing systolic blood pressure decrease mean 4-5 mmHg at 10 mg and up to 7-8 mmHg at 20 mg in young volunteers - larger in elderly on thiazide plus ACE inhibitor triple therapy.

Card note: vardenafil diabetic trial IIEF-EF mean change exceeded placebo by 5-7 points at 20 mg at 12 weeks - comparable magnitude to sildenafil diabetic subgroup publications from same era.

Staxyn orodispersible bioavailability slightly higher than film-coated in fasting PK substudies but still subject to food effect for swallowed portion - do not market ODT as meal-proof.

Retinal artery occlusion case reports exist in FAERS for all PDE5 agents; causal inference weak - still stop drug and urgent ophthalmology if acute monocular vision loss.

Generic vardenafil withdrawal from some wholesalers reflects commercial demand not safety withdrawal - check distribution before telling patient agent is discontinued nationally.

Alpha-blocker doxazosin 4 mg co-administration with vardenafil produced more symptomatic hypotension than tamsulosin 0.4 mg in historical interaction studies - prefer tamsulosin if alpha-blocker required.

Vardenafil 20 mg does not inhibit platelet aggregation ex vivo at therapeutic concentrations - antiplatelet therapy for CAD is not a contraindication though bleeding risk from trauma is unchanged.

Orodispersible formulation peak plasma slightly earlier than film-coated in fasting subjects - onset counseling may use 45-60 minute window for Staxyn on empty stomach.

Vardenafil labeling contraindicates use in patients on nitrates and in patients where sexual activity is inadvisable - second clause reminds prescribers that drug is not the only cardiovascular gate.

Men with LVAD or advanced heart failure rarely appear in ED trials - individual specialist clearance required; vardenafil hemodynamics in low-output states are not studied.

Class trial completion means sildenafil 100 mg, tadalafil 20 mg PRN or 5 mg daily, and vardenafil 20 mg each given fair structured attempts before invasive therapy - document doses tried.

Card note: penile fibrosis and Peyronie plaque curvature may limit expansion despite adequate cGMP - urology evaluation when rigidity is asymmetric or painful.